Plain-English translation of NCT05348213 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a personalized approach to treating aggressive B-cell lymphoma that has come back or stopped responding to initial treatment. Doctors will first analyze your cancer's genetic makeup to determine which of several targeted medications—including Zanubrutinib, Decitabine, Chidamide, Tofacitinib, or Pomalidomide—might work best for you. You'll receive the medication combined with a standard chemotherapy regimen called R-ICE, and after 3 months, doctors will check how well it's working.
Many patients with this type of aggressive lymphoma do not respond well enough to standard chemotherapy alone, and their cancer can come back. This trial explores whether giving each person a targeted drug matched to their cancer's specific genetic characteristics—in addition to chemotherapy—can improve their chances of recovery.
You likely qualify if…
You likely don't qualify if…
First, doctors will perform genetic testing on your cancer to identify which targeted medication is best suited for you. You'll receive the targeted medication combined with chemotherapy (R-ICE regimen) over the course of your treatment. After 3 months, you'll have imaging scans to see how well the treatment is working. Depending on your response and age, you may either continue with stem cell transplantation or stay on the targeted medication for up to 12 months. You'll have follow-up visits every 3 months in the first year, then every 6 months for the next two years.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China